SHINCORT
Small molecule
SHINCORT is one of 33 small molecule programs targeting Carpal Tunnel Syndrome. It is currently in development.
1
Indications
1
Total Trials
0
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
66 competitors in Carpal Tunnel Syndrome
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
Neurontin
VViatris Specialty LLC
Approved
Decadron
AAspen Global Incorporated
Approved
Advil
KKenvue Brands
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
N-Acetyl Cyteien
SStanford University
Approved
Celestone
SSchering-Plough
Phase 3
Epidiolex
Jazz PharmaceuticalsPhase 2
Xylocaine
AstraZenecaPhase 3
Acetyl-L-Carnitine
Mario Negri Institute for Pharmacological ResearchPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHINCORT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]